20982 related articles for article (PubMed ID: 24606795)
1. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of drug-based neuroprotection targeting mitochondria.
Procaccio V; Bris C; Chao de la Barca JM; Oca F; Chevrollier A; Amati-Bonneau P; Bonneau D; Reynier P
Rev Neurol (Paris); 2014 May; 170(5):390-400. PubMed ID: 24792485
[TBL] [Abstract][Full Text] [Related]
3. Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.
Komen JC; Thorburn DR
Br J Pharmacol; 2014 Apr; 171(8):1818-36. PubMed ID: 24102298
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming of human cells in response to oxidative stress: implications in the pathophysiology and therapy of mitochondrial diseases.
Wu YT; Wu SB; Wei YH
Curr Pharm Des; 2014; 20(35):5510-26. PubMed ID: 24606797
[TBL] [Abstract][Full Text] [Related]
5. The neurogenic basic helix-loop-helix transcription factor NeuroD6 confers tolerance to oxidative stress by triggering an antioxidant response and sustaining the mitochondrial biomass.
Uittenbogaard M; Baxter KK; Chiaramello A
ASN Neuro; 2010 May; 2(2):e00034. PubMed ID: 20517466
[TBL] [Abstract][Full Text] [Related]
6. Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease.
Ferretta A; Gaballo A; Tanzarella P; Piccoli C; Capitanio N; Nico B; Annese T; Di Paola M; Dell'aquila C; De Mari M; Ferranini E; Bonifati V; Pacelli C; Cocco T
Biochim Biophys Acta; 2014 Jul; 1842(7):902-15. PubMed ID: 24582596
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.
Chaturvedi RK; Beal MF
Mol Cell Neurosci; 2013 Jul; 55():101-14. PubMed ID: 23220289
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol-Mediated Regulation of Mitochondria Biogenesis-associated Pathways in Neurodegenerative Diseases: Molecular Insights and Potential Therapeutic Applications.
Shaito A; Al-Mansoob M; Ahmad SMS; Haider MZ; Eid AH; Posadino AM; Pintus G; Giordo R
Curr Neuropharmacol; 2023; 21(5):1184-1201. PubMed ID: 36237161
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation.
Fang WJ; Wang CJ; He Y; Zhou YL; Peng XD; Liu SK
Acta Pharmacol Sin; 2018 Jan; 39(1):59-73. PubMed ID: 28770830
[TBL] [Abstract][Full Text] [Related]
10. Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo.
Hofer A; Noe N; Tischner C; Kladt N; Lellek V; Schauß A; Wenz T
Hum Mol Genet; 2014 May; 23(9):2400-15. PubMed ID: 24334768
[TBL] [Abstract][Full Text] [Related]
11. SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of resveratrol against neurodevelopment damage by fluoride.
Zhao Q; Tian Z; Zhou G; Niu Q; Chen J; Li P; Dong L; Xia T; Zhang S; Wang A
Theranostics; 2020; 10(11):4822-4838. PubMed ID: 32308752
[No Abstract] [Full Text] [Related]
12. Resveratrol Promotes Mitochondrial Biogenesis and Protects against Seizure-Induced Neuronal Cell Damage in the Hippocampus Following Status Epilepticus by Activation of the PGC-1α Signaling Pathway.
Chuang YC; Chen SD; Hsu CY; Chen SF; Chen NC; Jou SB
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823590
[TBL] [Abstract][Full Text] [Related]
13. NARP mutation and mtDNA depletion trigger mitochondrial biogenesis which can be modulated by selenite supplementation.
Wojewoda M; Duszyński J; Szczepanowska J
Int J Biochem Cell Biol; 2011 Aug; 43(8):1178-86. PubMed ID: 21550418
[TBL] [Abstract][Full Text] [Related]
14. Salicylates promote mitochondrial biogenesis by regulating the expression of PGC-1α in murine 3T3-L1 pre-adipocytes.
Yan Y; Yang X; Zhao T; Zou Y; Li R; Xu Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):436-441. PubMed ID: 28712868
[TBL] [Abstract][Full Text] [Related]
15. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
Pirooznia SK; Yuan C; Khan MR; Karuppagounder SS; Wang L; Xiong Y; Kang SU; Lee Y; Dawson VL; Dawson TM
Mol Neurodegener; 2020 Mar; 15(1):17. PubMed ID: 32138754
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic screening of mitochondrial DNA mutations in Australian adults 1990-2001.
Marotta R; Chin J; Quigley A; Katsabanis S; Kapsa R; Byrne E; Collins S
Intern Med J; 2004; 34(1-2):10-9. PubMed ID: 14748908
[TBL] [Abstract][Full Text] [Related]
17. Mutual Antagonism of PINK1/Parkin and PGC-1α Contributes to Maintenance of Mitochondrial Homeostasis in Rotenone-Induced Neurotoxicity.
Peng K; Xiao J; Yang L; Ye F; Cao J; Sai Y
Neurotox Res; 2019 Feb; 35(2):331-343. PubMed ID: 30242625
[TBL] [Abstract][Full Text] [Related]
18. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations.
Wenz T; Wang X; Marini M; Moraes CT
J Cell Mol Med; 2011 Nov; 15(11):2317-25. PubMed ID: 21129152
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in the molecular genetics of mitochondrial disorders.
Graeber MB; Müller U
J Neurol Sci; 1998 Jan; 153(2):251-63. PubMed ID: 9511882
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
